HC Wainwright Predicts Geron's Q3 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN - Free Report) - Equities researchers at HC Wainwright dropped their Q3 2025 earnings per share estimates for shares of Geron in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter, down from their previous estimate of ($0.02). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron's Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.13) EPS, FY2026 earnings at ($0.11) EPS and FY2027 earnings at ($0.04) EPS.

Geron (NASDAQ:GERN - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company had revenue of $39.60 million for the quarter, compared to the consensus estimate of $49.88 million. During the same period in the prior year, the company posted ($0.07) EPS. The company's revenue was up 12927.3% compared to the same quarter last year.

A number of other research firms have also commented on GERN. Scotiabank lowered shares of Geron from a "sector outperform" rating to a "sector perform" rating and lowered their target price for the stock from $4.00 to $1.50 in a report on Thursday, May 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $5.00 target price on shares of Geron in a report on Wednesday, March 12th. Stifel Nicolaus lowered their target price on shares of Geron from $8.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Barclays reissued an "overweight" rating and issued a $4.00 target price (down previously from $9.00) on shares of Geron in a research note on Thursday, February 27th. Finally, B. Riley lowered Geron from a "buy" rating to a "neutral" rating and cut their target price for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.06.

Geron Trading Down 0.8%

Geron stock traded down $0.01 during trading hours on Monday, reaching $1.19. 5,926,391 shares of the company's stock traded hands, compared to its average volume of 11,566,522. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a fifty-two week low of $1.17 and a fifty-two week high of $5.34. The firm has a market capitalization of $757.93 million, a price-to-earnings ratio of -3.72 and a beta of 0.76. The firm's 50 day moving average is $1.47 and its 200-day moving average is $2.69.

Hedge Funds Weigh In On Geron

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Geron by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 34,146,851 shares of the biopharmaceutical company's stock valued at $54,293,000 after purchasing an additional 608,029 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Geron by 20.0% during the fourth quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company's stock worth $95,769,000 after acquiring an additional 4,516,615 shares during the period. Wellington Management Group LLP raised its holdings in shares of Geron by 6.7% during the fourth quarter. Wellington Management Group LLP now owns 13,510,114 shares of the biopharmaceutical company's stock worth $47,826,000 after acquiring an additional 847,710 shares during the period. Geode Capital Management LLC raised its holdings in shares of Geron by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 13,141,514 shares of the biopharmaceutical company's stock worth $46,531,000 after acquiring an additional 73,515 shares during the period. Finally, Woodline Partners LP raised its holdings in shares of Geron by 64.6% during the fourth quarter. Woodline Partners LP now owns 11,587,344 shares of the biopharmaceutical company's stock worth $41,019,000 after acquiring an additional 4,549,031 shares during the period. 73.71% of the stock is currently owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.